Alessandro Belvedere

Alessandro Belvedere

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
GAGrandioso Alessia
Grandioso Alessia
PTPaolo Tollis
Paolo Tollis
PRPellegrini Francesca Romana
Pellegrini Francesca Romana
EFElisabetta Falvo
Elisabetta Falvo
APAlessandro Palma
Alessandro Palma
PLPietro Laneve
Pietro Laneve
Background: Group 3 (G3) is one of the most common, aggressive and fatal subtypes of the paediatric cerebellar tumour Medulloblastoma (MB), primarily driven by the MYC oncogene. Targeting MYC has long been challenging and this, combined with our incomplete understanding of G3 MB molecular bases, has hindered the development of effective targeted therapies. Long noncoding RNAs (lncRNAs), with their extensive oncogenic roles, cancer-specific expression, and connection to MYC biology, offer opportunities for unravelling this complexity and providing new insights and therapeutic targets. Methodology: Using genome-wide, molecular and cellular assays, we characterised the activity of the MYC-dependent, anti-apoptotic lncRNA lncMB3 in G3 MB cells. Results: Through transcriptomic and interactomic analyses, we clarified lncMB3 function and mode-of-action. LncMB3 controls the TGF-β pathway, critically altered in G3 medulloblastomagenesis. This regulation occurs via the direct coding-noncoding RNA interaction between lncMB3 and the mRNA for the epigenetic factor HMGN5, with both sharing targets in the TGF-β cascade. This axis converges on apoptosis through OTX2, another G3 MB driver gene, and photoreceptor lineage genes. Synergistic effects between lncMB3 targeting and cisplatin treatment underscores the relevance of this regulatory network in vitro . Finally, we propose novel ferritin-based nanocarriers as efficient delivery tools for antisense oligonucleotides targeting lncMB3 . Conclusions: LncMB3 emerges as a central node linking MYC amplification to apoptosis inhibition through a circuit involving RNA-based mechanisms, G3 MB key drivers and underexplored factors. This integrated framework deepens our understanding of G3 MB molecular underpinnings and lay the foundation for translating lncRNA research into potential applications.

18 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
PTPaolo Tollis
Paolo Tollis
TSTiziana Santini
Tiziana Santini
ASAdriano Setti
Adriano Setti
WVWalter Visciglio
Walter Visciglio
JRJessica Rea
Jessica Rea
PLPietro Laneve
Pietro Laneve
Long noncoding RNAs (lncRNAs) are well recognized as regulators of neuronal development and function, yet their integration into canonical axonal transport pathways, an essential component of spatial gene regulation in highly polarized cells, remains incompletely defined. It is still unclear to what extent individual lncRNAs confer cargo selectivity and couple discrete mRNA cohorts to established transport machineries. Here we identify a cytoplasmic role for the neuronal isoform of HOTAIRM1 ( nHOTAIRM1 ) in shaping the axonal RNA landscape of human iPSC-derived spinal motor neurons (spMNs). We show that nHOTAIRM1 associates with Annexin A11 (ANXA11), a factor linked to lysosome-coupled movement of RNA granules and engages a defined subset of MN-relevant mRNAs. Transcriptome-wide and targeted interaction assays, together with computational mapping and steric competition, support direct RNA-RNA pairing between nHOTAIRM1 and mRNAs involved in cytoskeletal organization and synaptic or vesicular functions, while spatial analyses place these RNA pairs in close proximity within the soma and neurites. Loss-of-function experiments further show that nHOTAIRM1 depletion reduces the association of these mRNAs with ANXA11-positive complexes and diminishes their enrichment in neuronal projections, an effect that is recapitulated by ANXA11 depletion. Collectively, these findings support a model in which nHOTAIRM1 contributes to the selective recruitment of cargo mRNAs into ANXA11-associated transport assemblies, thereby promoting their localization within distal neurites. More broadly, our findings provide mechanistic insight into how a lncRNA can regulate mRNA sorting and compartment-specific RNA trafficking in human spMNs.

17 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
PTPaolo Tollis
Paolo Tollis
ABAlessandro Belvedere
Alessandro Belvedere
AGAlessia Grandioso
Alessia Grandioso
MBMonica Ballarino
Monica Ballarino
PLPietro Laneve
Pietro Laneve
Despite advances in surgery, radiotherapy, chemotherapy and targeted treatments, resistance remains a major obstacle in nervous system (NS) tumours. Treatment failure reflects not only individual oncogenic alterations but also adaptive regulatory networks that enable tumour cells to survive therapeutic stress, maintain plasticity and adopt therapy-tolerant phenotypes. Within these networks, long non-coding RNAs (lncRNAs) have emerged as potential therapeutic targets because of their spatiotemporal expression patterns, context-dependent functions and ability to coordinate gene-expression programmes. Advances in RNA therapeutics provide tools to exploit these properties by targeting disease-associated transcripts and RNA-dependent interactions that are difficult to address with conventional small molecules or antibodies. Studies in NS tumour models have implicated lncRNAs as determinants of therapeutic responses, including DNA repair, apoptotic thresholds, stem-like states, mesenchymal-like plasticity, invasion, metabolic adaptation and stress responses, as well as intercellular communication within the tumour microenvironment. Targeting oncogenic lncRNAs may weaken resistance programmes and enhance the activity of partner treatments, providing a rationale for combinations that could maintain antitumour efficacy at lower drug doses. In this Review, we discuss the rationale for targeting lncRNAs to influence therapeutic response in NS tumours. The evidence is concentrated in gliomas, particularly glioblastoma, with additional studies in other entities. We summarise preclinical evidence for combining lncRNA-directed interventions with chemotherapy or radiotherapy, distinguishing changes in treatment sensitivity and resistance from quantitatively demonstrated synergy. We discuss targeting strategies, including antisense oligonucleotides, siRNAs and interaction-disrupting approaches, and consider translational challenges related to target selection, context-dependent biology, tumour heterogeneity, intracellular accessibility, delivery to tumours and potential toxicity to normal tissues. Collectively, these findings support lncRNAs as potentially actionable regulatory nodes and provide a foundation for developing more effective and better-tolerated combinatorial strategies in NS tumours.